> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Fast Track for Bayer Blood Thinner
- URL: https://www.fdaweb.com/fda-fast-track-for-bayer-blood-thinner/
- Published: 2022-02-10T12:00:00.000Z
- Updated: 2026-09-14T17:32:10.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5151139

FDA has granted Bayer a fast track designation for its investigational blood thinner asundexian (BAY2433334) as a potential treatment for secondary prevention in patients with a non-cardioembolic ischemic stroke. The company describes asundexian as an oral inhibitor of Factor XIa (FXIa) that Bayer is developing as a potential treatment for secondary prevention in patients with a non-cardioembolic ischemic stroke as well as atrial fibrillation and recent myocardial infarction. It is currently in Phase 2 clinical trials in all three indications either as monotherapy, or in combination with anti-platelet therapy. “Inhibition of FXIa by asundexian is hypothesized to provide protection from thrombotic events without increasing the risk of bleeding,” the company says.